Clinical Trial Update: Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC [EARLY_Phase 1]

View source ↗

Summary

Completed early-phase 1 study evaluating biodistribution and reproducibility of the Ga-68 PSMA-HBED-CC radiotracer in prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-HBED-CC (Ga-68 labeled PSMA-HBED-CC radiopharmaceutical)

Snippet

Sponsor: University of Iowa | Conditions: Prostatic Neoplasms | EARLY_Phase 1 | Status: COMPLETED